Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21987727 | 0.94 | SMN1; SMN2 (0.43) | SMN1; SMN2GAAHTTALDH1A1LMNA | |
| SCHEMBL21987790 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAHTTALDH1A1LMNA | |
| SCHEMBL19995380 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAHTTALDH1A1LMNA | |
| SCHEMBL18707162 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL1576143 | 0.85 | GAA (0.49) | SMN1; SMN2GAAALDH1A1NPC1RAB9A | |
| SCHEMBL21995317 | 0.83 | HPGD (0.43) | SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL20954393 | 0.81 | MGAM (0.37) | SMN1; SMN2GAAHTTALDH1A1POLB | |
| SCHEMBL221809 | 0.80 | GAA (0.46) | SMN1; SMN2GAA | |
| SCHEMBL21987333 | 0.80 | ALDH1A1 (0.43) | SMN1; SMN2GAAHTTALDH1A1LMNA | |
| SCHEMBL9938875 | 0.79 | HPGD (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | SMN1; SMN2 4696/4885GAA 1238/4885HTT 3871/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | SMN1; SMN2 4624/4885GAA 2071/4885HTT 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.